Single and multiple-dose pharmacokinetics, safety and tolerability of ertugliflozin in Chinese healthy subjects: A phase I, open-label, parallel-cohort, randomized study

Trial Profile

Single and multiple-dose pharmacokinetics, safety and tolerability of ertugliflozin in Chinese healthy subjects: A phase I, open-label, parallel-cohort, randomized study

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Jan 2018

At a glance

  • Drugs Ertugliflozin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 10 Jan 2018 New trial record
    • 08 Dec 2017 Results presented at the 2017 Congress of the International Diabetes Federation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top